Search Results

Long-Term PERSEUS Data Published for Boston Scientific's Taxus Element Ion PES

March 9, 2015—Dean J. Kereiakes, MD, et al published 5-year results from the PERSEUS Workhorse (WH) and Small Vessel (SV) trials of Boston Scientific’s Taxus Element Ion device. The Taxus Element Ion is a platinum-chromium paclitaxel-eluting stent (PtCr-PES) that incorporates a thin (81-μm) strut design with a similar polymer and drug dose density as previous PESs. The results are available online ahead of print in Catheterization and Cardiovascular Interventions.

Analysis of SPIRIT and COMPARE Data Supports Abbott Vascular's Xience V

April 3, 2011—Abbott Vascular (Santa Clara, CA) announced that Dean J. Kereiakes, MD, presented 2-year results on the safety and efficacy of the company's Xience V everolimus-eluting coronary stent system compared to Taxus Liberté and Taxus Express2 paclitaxel-eluting coronary stent systems (Boston Scientific Corporation, Natick, MA) at the American College of Cardiology's (ACC) 60th annual scientific session in New Orleans.

Twelve-Month EVOLVE II Data Published for Boston Scientific's Synergy Bioabsorbable EES

April 8, 2015—The 12-month data from the EVOLVE II were published by Dean J. Kereiakes, MD, et al online ahead of print in Circulation: Cardiovascular Interventions. EVOLVE II is a randomized trial evaluating the efficacy and safety of the Synergy (Boston Scientific Corporation) bioabsorbable polymer-coated, everolimus-eluting coronary stent.

Abbott Vascular's Absorb BVS Studied in Patients With Diabetes Mellitus

January 13, 2017—Findings from the Absorb Diabetic Substudy of Abbott Vascular's Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were published by Dean J. Kereiakes, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2017;10:42–49). The investigators concluded that the substudy, "suggests the efficacy and safety of the Absorb BVS for treatment of patients with diabetes mellitus."

Three-Year ABSORB III Trial Data Presented and Published for Abbott Vascular's BVS

October 31, 2017—The ABSORB III study assessed clinical outcomes through 3 years after implantation of the Absorb everolimus-eluting poly-L-lactic acid–based bioresorbable vascular scaffold (BVS; Abbott Vascular).

PERSEUS, TAXUS ATLAS

April 3, 2011—Boston Scientific Corporation (Natick, MA) announced results from a pooled patient-level analysis of its PERSEUS (PERSEUS Workhorse and PERSEUS Small Vessel) and TAXUS ATLAS clinical trial data, demonstrating favorable safety and efficacy outcomes of the company's next-generation Ion platinum chromium (PtCr) paclitaxeleluting stent system (Taxus Element) compared to the currently available Taxus Liberté paclitaxel-eluting stent system.

Pooled Data Support Boston Scientific's Ion PtCr Stent System

April 3, 2011—Boston Scientific Corporation (Natick, MA) announced results from a pooled patient-level analysis of its PERSEUS (PERSEUS Workhorse and PERSEUS Small Vessel) and TAXUS ATLAS clinical trial data, demonstrating favorable safety and efficacy outcomes of the company's next-generation Ion platinum chromium (PtCr) paclitaxel-eluting stent system (Taxus Element) compared to the currently available Taxus Liberté paclitaxel-eluting stent system.

Svelte Medical Systems' Slender IDS DES Evaluated in OPTIMIZE Trial

October 17, 2020—The OPTIMIZE randomized trial evaluated a novel, low-profile drug-eluting stent (DES) facilitating transradial (TR) access and direct stenting (DS) in comparison to an existing DES.

Shockwave Medical’s Intravascular Lithotripsy System Evaluated in Three Published Studies

June 28, 2021—Shockwave Medical, Inc. announced the publication of evaluations of the safety, efficacy, and mechanism of the benefit of the company’s intravascular lithotripsy (IVL) for the treatment of coronary and peripheral artery disease (PAD).

SCAI Bestows Master Interventionalists Designation on 10 Cardiologists

May 10, 2022—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the designations of its 2022 Master Interventionalists of SCAI (MSCAI).

Orchestra BioMed’s Pivotal Trial of Virtue SAB for Coronary ISR Begins Enrollment

November 10, 2025—Orchestra BioMed Holdings, Inc. announced that the first patients were enrolled in the United States investigational device exemption (IDE) pivotal study for the company’s Virtue sirolimus angioinfusion balloon (Virtue SAB) in the treatment of coronary in-stent restenosis (ISR).

Five-Year DESSOLVE Data Presented for Micell Technologies' MiStent

November 7, 2016—Micell Technologies, Inc. announced 5-year clinical safety and efficacy results from the DESSOLVE I and DESSOLVE II trials of the company’s MiStent sirolimus-eluting absorbable polymer coronary stent system.

Orchestra BioMed Granted IDE Approval for Virtue ISR-US Pivotal Study of Virtue SAB Device

August 8, 2023—Orchestra BioMed Holdings, Inc. announced that the FDA granted investigational device exemption (IDE) approval with conditions to initiate the Virtue ISR-US pivotal study evaluating the efficacy and safety of the company’s Virtue sirolimus angio-infusion balloon (SAB) for the treatment of patients with coronary in-stent restenosis (ISR).

FDA Approves Boston Scientific's Ion PtCr Stent System

April 25, 2011—Boston Scientific Corporation (Natick, MA) announced US Food and Drug Administration (FDA) approval and the launch of the Ion paclitaxel-eluting platinum chromium (PtCr) coronary stent system. The Ion stent will be available with sizes ranging in diameter from 2.25 to 4 mm and lengths from 8 to 38 mm, and includes both monorail and over-the-wire versions.

Abbott Completes Enrollment of ABSORB Trials in US, Japan, and China

April 10, 2014—Abbott Vascular (Santa Clara, CA) announced that it has completed enrollment of three randomized clinical trials to support approvals of the company’s everolimus-eluting Absorb bioresorbable vascular scaffold (BVS) in the United States, Japan, and China.